Home ›
Lymphoma Trials ›
NCT05182957
Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma
Aim of this study will evaluate the Efficacy and Safety of Anti-PD-1 monoclonal antibody Combined Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma Patients.
Trial Details
NCT ID NCT05182957
Phase PHASE2
Sponsor The First Affiliated Hospital of Soochow University
Status RECRUITING
Cancer Type Lymphoma
Interventions Anti-PD-1 monoclonal antibody Lenalidomide Azacitidine
Locations (sample) Suzhou, Jiangsu, China|31.30408,120.59538
Key Eligibility Criteria
Pathological immunohistochemistry or flow cytometry confirmed that R/R PTCL with measurable (diameter greater than 1.5cm) lesions meets any of the … Age ≥ 18 years. The main organ functions need to meet the following conditions:Hemogram needs to meet HB ≥70\*1012/L,PLT≥50\*109/L,NE≥1\*109/L;LVEF≥50%;CR≤132umol/… Subjects of child-bearing or child-fathering potential must be willing to practice birth control from the time of enrollment on this study until th…
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Lymphoma Trials on Trialify →